Literature DB >> 23594009

Mediating resistance in oncogene-driven cancers.

Rafael Rosell1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23594009     DOI: 10.1056/NEJMcibr1214549

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.

Authors:  Senthil Damodaran; Fengmin Zhao; Dustin A Deming; Edith P Mitchell; John J Wright; Robert J Gray; Victoria Wang; Lisa M McShane; Larry V Rubinstein; David R Patton; P Mickey Williams; Stanley R Hamilton; Jennifer M Suga; Barbara A Conley; Carlos L Arteaga; Lyndsay N Harris; Peter J O'Dwyer; Alice P Chen; Keith T Flaherty
Journal:  J Clin Oncol       Date:  2022-02-08       Impact factor: 50.717

Review 2.  The emerging role of mediator complex subunit 12 in tumorigenesis and response to chemotherapeutics.

Authors:  Shengjie Zhang; Ruth O'Regan; Wei Xu
Journal:  Cancer       Date:  2019-12-23       Impact factor: 6.860

3.  Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming.

Authors:  Praveena S Thiagarajan; Xiaoliang Wu; Wei Zhang; Ivy Shi; Rakesh Bagai; Patrick Leahy; Yan Feng; Martina Veigl; Daniel Lindner; David Danielpour; Lihong Yin; Rafael Rosell; Trever G Bivona; Zhenfeng Zhang; Patrick C Ma
Journal:  Oncotarget       Date:  2016-12-13

Review 4.  Interrogating the Genomic Landscape of Uterine Leiomyosarcoma: A Potential for Patient Benefit.

Authors:  Genevieve V Dall; Anne Hamilton; Gayanie Ratnayake; Clare Scott; Holly Barker
Journal:  Cancers (Basel)       Date:  2022-03-18       Impact factor: 6.639

Review 5.  Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities.

Authors:  Rafael Rosell; Andrés Felipe Cardona; Oscar Arrieta; Andrés Aguilar; Masaoki Ito; Carlos Pedraz; Jordi Codony-Servat; Mariacarmela Santarpia
Journal:  Br J Cancer       Date:  2021-08-09       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.